Kinetic study of a 2-hydroxypropyl-β-cyclodextrin-based formulation of all-trans-retinoic acid in Sprague-Dawley rats after oral or intravenous administration
Hai-Shu Lin
Department of Pharmacy, National University of Singapore, 10 Kent Ridge Crescent, Singapore 119260
Search for more papers by this authorSui Yung Chan
Department of Pharmacy, National University of Singapore, 10 Kent Ridge Crescent, Singapore 119260
Search for more papers by this authorKerwin Siew Yang Low
Department of Pharmacology, National University of Singapore, 10 Kent Ridge Crescent, Singapore 119260
Search for more papers by this authorMei Leng Shoon
Department of Pharmacology, National University of Singapore, 10 Kent Ridge Crescent, Singapore 119260
Search for more papers by this authorCorresponding Author
Paul C. Ho
Department of Pharmacy, National University of Singapore, 10 Kent Ridge Crescent, Singapore 119260
Department of Pharmacy, National University of Singapore, 10 Kent Ridge Crescent, Singapore 119260Search for more papers by this authorHai-Shu Lin
Department of Pharmacy, National University of Singapore, 10 Kent Ridge Crescent, Singapore 119260
Search for more papers by this authorSui Yung Chan
Department of Pharmacy, National University of Singapore, 10 Kent Ridge Crescent, Singapore 119260
Search for more papers by this authorKerwin Siew Yang Low
Department of Pharmacology, National University of Singapore, 10 Kent Ridge Crescent, Singapore 119260
Search for more papers by this authorMei Leng Shoon
Department of Pharmacology, National University of Singapore, 10 Kent Ridge Crescent, Singapore 119260
Search for more papers by this authorCorresponding Author
Paul C. Ho
Department of Pharmacy, National University of Singapore, 10 Kent Ridge Crescent, Singapore 119260
Department of Pharmacy, National University of Singapore, 10 Kent Ridge Crescent, Singapore 119260Search for more papers by this authorAbstract
all-trans-Retinoic acid (ATRA, vitamin A acid, or tretinoin) is a potent chemotherapeutic agent for the treatment of acute promyelocytic leukemia (APL). Its poor aqueous solubility not only affects its oral absorption but also prevents it from forming an aqueous parenteral formulation. Recently, we developed a water-soluble formulation of ATRA with 2-hydroxypropyl-β-cyclodextrin (HPβCD). In present study, this formulation was tested in Sprague-Dawley rats. Kinetic study of ATRA was carried out after oral or intravenous administration. Though there were no statistical differences in any of the estimated pharmacokinetic parameters between ATRA sodium salt and HPβCD-based ATRA after intravenous administration, inclusion of ATRA into HPβCD was found to greatly improve the oral absorption of ATRA. © 2000 Wiley-Liss, Inc. and the American Pharmaceutical Association J Pharm Sci 89: 260–267, 2000
REFERENCES AND NOTES
- 1Regazzi MB, Iacona I, Gervasutti C, Lazzarino M. 1997. Clinical pharmacokinetics of tretinoin. Clin Pharmacokinet 32: 382.
- 2Warrell RP, Dethe H, Wang ZY, Degos L. 1993. Acute promyelocytic leukemia. N Engl J Med 329: 177.
- 3Gillis JC, Goa KL. 1995. Tretinoin-A review of its pharmacodynamic and pharmacokinetic properties and use in the management of acute promyelocytic leukaemia. Drugs 50: 897.
- 4Tallman MS, Andersen JW, Schiffer CA, Appelbaum FR, Feusner JH, Ogden A, Shepherd L, Willman C, Bloomfield CD, Rowe JM, Wiernik PH. 1997. All-trans-retinoic acid in acute promyelocytic leukemia. N Engl J Med 337: 1021.
- 5 Physicians' Desk Reference (PDR). 53th edition. 1999. Montvale: Medical Economics Company. p 2726–2727.
- 6Adamson PC, Pitot HC, Balis FM, Rubin J, Murphy RF, Poplack DG. 1993. Variability in the oral bioavailability of all-trans-retinoic acid. J Natl Cancer Inst 85: 993.
- 7Lazzarino M, Regazzi MB, Corso A. 1996. Clinical relevance of all-trans retinoic acid pharmacokinetics and its modulation in acute promyelocytic leukemia. Leuk Lymphoma 23: 539.
- 8Kueh YK, Liew PPL, Ho PC, Wu TS. 1999. Sublingual administration of all-trans-retinoic acid to a comatose patient with in acute promyelocytic leukemia. Ann Pharmcother 33: 503.
- 9Drach J, Lopez-Berestein G, McQueen T, Andreeff M, Mehta K. 1993. Induction of differentiation in myeloid leukemia cell lines and acute promyelocytic leukemia cells by liposomal all-trans-retinoic acid. Cancer Res 53: 2100.
- 10Mehta K, Sadeghi T, McQueen T, Lopez-Berestein G. 1994. Liposome encapsulation circumvents the hepatic clearance mechanisms of all-trans-retinoic acid. Leuk Res 18: 587.
- 11Estey E, Thall PF, Mehta K, Rosenblum M, Brewer T Jr, Simmons V, Cabanillas F, Kurzrock R, Lopez-Berestein G. 1996. Alterations in tretinoin pharmacokinetics following administration of liposomal all-trans retinoic acid. Blood 87: 3650.
- 12Loftsson T, Brewster ME. 1996. Pharmaceutical applications of cyclodextrins 1. Drug solubilization and stabilization. J Pharm Sci 85: 1017.
- 13Rajewski RA, Stella VJ. 1996. Pharmaceutical applications of cyclodextrins. 2. In vivo drug delivery. J Pharm Sci 85: 1142.
- 14Thompson DO. 1997. Cyclodextrins (enabling excipients: their present and future use in pharmaceuticals. Crit Rev Ther Drug Carrier Syst 14: 1.
- 15Irie T, Uekama K. 1997. Pharmaceutical applications of cyclodextrins. III. Toxicological issues and safety evaluation. J Pharm Sci 86; 147.
- 16Stella VJ, Rajewski RA. 1997. Cyclodextrins: Their future in drug formulation and delivery. Pharm Res 14: 556.
- 17Zhou HH, Goldman M, Wu J, Woestenborghs R, Hassell AE, Lee P, Baruch A, Pesco-Koplowitz L, Borum J, Wheat LJ. 1998. A pharmacokinetic study of intravenous itraconazole followed by oral administration of itraconazole capsules in patients with advanced human immunodeficiency virus infection. J Clin Pharmacol 38: 593.
- 18Ng YY, Liew PPL, Yamamoto K, Yonemochi E, Oguchi T, Ho PC. 1998. Solubilization of all-trans-retinoic acid with cyclodextrin derivatives. Conference on challenges for drug delivery and pharmaceutical technology. Shinjuku-ku, Tokyo, Japan: Waseda University. p 185.
- 19Guiso G, Rambaldi A, Dimitrova B, Biondi A, Caccia S. 1994. Determination of orally administered all-trans-retinoic acid in human plasma by high-performance liquid chromatography. J Chromatogr B 656: 239.
- 20Shelley RS, Jun HW, Price JC, Cadwallader DE. 1982. Blood level studies of all-trans- and 13-cis-retinoic acids in rats using different formulations. J Pharm Sci 71: 904.
- 21El Mansouri S, Tod M, Leclerq M, Petitjean O, Perret G, Porthault M. 1995. Time- and dose-dependent kinetics of all-trans-retinoic acid in rats after oral or intravenous administration(s). Drug Metab Dispos 23: 227.
- 22Adamson PC, Balis FM, Smith MA, Murphy RF, Godwin KA, Poplack DG. 1992. Dose-dependent pharmacokinetics of all-trans-retinoic acid. J Natl Cancer Inst 84: 1332.
- 23Swanson BN, Frolik CA, Zaharevitz DW, Roller PP, Sporn MB. 1981. Dose-dependent kinetics of all-trans-retinoic acid in rats. Plasma levels and excretion into bile, urine, and faeces. Biochem Pharmacol 30: 107.
- 24Montassier P, Duchene D, Poelman MC. 1997. Inclusion complexes of tretinoin with cyclodextrins. Int J Pharm 153: 199.
- 25Frijlink HW, Franssen EJ, Eissens AC, Oosting R, Lerk CF, Meijer DK. 1991. The effects of cyclodextrins on the disposition of intravenously injected drugs in the rat. Pharm Res 8: 380.
- 26Stella VJ, Rao VM, Zannou EA, Zia V. 1999. Mechanisms of drug release from cyclodextrin complexes. Adv Drug Deliv Rev 36: 3.
- 27Piel G, Evrard B, Van Hees T, Delattre L. 1999. Comparison of the IV pharmacokinetics in sheep of miconazole-cyclodextrin solutions and a micellar solution. Int J Pharm 180: 41.
- 28Han CH, Wiedmann TS. 1998. Spectral properties and ion dissociation behavior of retinoids—I. Aqueous solutions. Int J Pharm 172: 241.
- 29Han CH, Zimmerman CL, Wiedmann TS. 1998. Spectral properties and ionization behavior of retinoids, II. Bile salt solutions. Int J Pharm 172: 229.
- 30Li P, Tabibi SE, Yalkowsky SH. 1999. Solubilization of flavopiridol by pH control combined with cosolvents, surfactants, or complexants. J Pharm Sci 88: 945.